Literature DB >> 23403268

Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.

Peter M Okin1, Casper N Bang, Kristian Wachtell, Darcy A Hille, Sverre E Kjeldsen, Björn Dahlöf, Richard B Devereux.   

Abstract

BACKGROUND: Prevalent atrial fibrillation (AF) is associated with a higher sudden cardiac death (SCD) rate in some populations, and incident AF predicts increased mortality risk in the general population and after myocardial infarction. However, the relationship of SCD to new-onset AF is unclear. METHODS AND
RESULTS: The relationship of SCD to new-onset AF was evaluated in 8831 hypertensive patients with electrocardiographic left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline electrocardiogram, randomly assigned to losartan- or atenolol-based treatment. During 4.7±1.1 years mean follow-up, new-onset AF occurred in 701 patients (7.9%) and SCD in 151 patients (1.7%). In univariate Cox analyses, new-onset AF was associated with a >4-fold higher risk of SCD (hazard ratio, 4.69; 95% CI interval, 2.96-7.45; P<0.001). In multivariate Cox analyses adjusting for age, sex, race, diabetes mellitus, history of heart failure, myocardial infarction, ischemic heart disease, stroke, smoking, serum high-density lipoprotein cholesterol, creatinine, glucose, and urine albumin/creatinine ratio as standard risk factors, and for incident myocardial infarction, in-treatment use of digoxin, systolic and diastolic pressure, heart rate, QRS duration, Cornell voltage-duration product, and Sokolow-Lyon voltage left ventricular hypertrophy treated as time-varying covariates, new-onset AF remained associated with a >3-fold increased risk of SCD (hazard ratio, 3.13; 95% confidence interval, 1.87-5.24; P<0.001).
CONCLUSIONS: Development of new-onset AF identifies hypertensive patients at increased risk of SCD. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00338260.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403268     DOI: 10.1161/CIRCEP.112.977777

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  18 in total

1.  [Diagnosis of atrial fibrillation. From the standard ECG to analysis of electrograms].

Authors:  Malte Meesmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-06

2.  Fosinopril improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats.

Authors:  Zhi-Bin Huang; Chun-Yu Deng; Mao-Huan Lin; Gui-Yi Yuan; Wei Wu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-27       Impact factor: 3.000

Review 3.  Tools for risk stratification of sudden cardiac death: a review of the literature in different patient populations.

Authors:  Loheetha Ragupathi; Behzad B Pavri
Journal:  Indian Heart J       Date:  2014-01-11

Review 4.  The influence of sex on left ventricular remodeling in arterial hypertension.

Authors:  Marijana Tadic; Cesare Cuspidi; Guido Grassi
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

5.  Exercise, Physical Activity, and Cardiometabolic Health: Pathophysiologic Insights.

Authors:  Matthew J Belanger; Prashant Rao; Jeremy M Robbins
Journal:  Cardiol Rev       Date:  2022 May-Jun 01       Impact factor: 3.109

Review 6.  Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis.

Authors:  Pattara Rattanawong; Sikarin Upala; Tanawan Riangwiwat; Veeravich Jaruvongvanich; Anawin Sanguankeo; Wasawat Vutthikraivit; Eugene H Chung
Journal:  J Interv Card Electrophysiol       Date:  2018-01-13       Impact factor: 1.900

7.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

8.  IL-6 signalling in patients with acute ST-elevation myocardial infarction.

Authors:  Vibeke N Ritschel; Ingebjørg Seljeflot; Harald Arnesen; Sigrun Halvorsen; Thomas Weiss; Jan Eritsland; Geir Ø Andersen
Journal:  Results Immunol       Date:  2013-12-14

Review 9.  Sudden Cardiac Death in Patients with Heart Disease and Preserved Systolic Function: Current Options for Risk Stratification.

Authors:  Luigi Pannone; Giulio Falasconi; Lorenzo Cianfanelli; Luca Baldetti; Francesco Moroni; Roberto Spoladore; Pasquale Vergara
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

Review 10.  Left ventricular hypertrophy and sudden cardiac death.

Authors:  Grigorios Giamouzis; Apostolos Dimos; Andrew Xanthopoulos; John Skoularigis; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2021-06-28       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.